RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Vivus Inc.

A collection of news and information related to Vivus Inc. published by this site and its partners.

Top Vivus Inc. Articles see all

Displaying items 1-5
  • U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

    WASHINGTON (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.
  • Long-awaited diet pill gets U.S. approval

    Long-awaited diet pill gets U.S. approval
    (Reuters) - A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration. Made by Orexigen Therapeutics Inc, Contrave is a...

    Diet drug Qnexa: Don't get too carried away by new study

    The diet drug Qnexa helps obese people with weight-related medical conditions to lose more weight than those who take a dummy pill and could allow some to scale back on medications for diabetes, high blood pressure or cholesterol, according to a new study...

    Obesity drugs need heart studies, U.S. advisers say

    Obesity drugs need heart studies, U.S. advisers say
    SILVER SPRING, Maryland (Reuters) - Heart safety studies should be required for new obesity drugs, U.S. drug advisers said on Thursday, possibly adding a new hurdle to the drugs' approval. An advisory panel to the U.S. Food and Drug Administration...

    FDA shoots down another weight loss drug [Updated]

    FDA shoots down another weight loss drug [Updated]
    The FDA has told the makers of the proposed weight-loss drug Lorcaserin that it will not at this time approve the marketing of  the medication, citing concerns about its marginal effectiveness and about cancers that occurred at higher-than-usual rates...